Trial Profile
Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Larotrectinib (Primary)
- Indications Cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors Bayer
- 29 Oct 2019 Status changed from recruiting to completed.
- 09 May 2017 According to a Loxo Oncology media release, data from this trial (n =1) has been presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting.
- 24 Jan 2017 New trial record